Cathie Wood’s ARK ETFs have published their daily trades for Tuesday, May 13th, 2025, showcasing a series of strategic buy and sell moves across various sectors. The largest transaction of the day came as ARK sold a significant stake in Archer Aviation Inc (NYSE:ACHR), offloading 523,773 shares for a total value of approximately $4.76 million through its ARKK ETF.
On the buying side, ARK made a notable investment in Twist Bioscience Corp (NASDAQ:TWST), purchasing 81,131 shares valued at roughly $2.67 million through the ARKK ETF. This move aligns with ARK’s focus on genomics and biotech innovation, sectors that have seen increased emphasis in their recent trading patterns.
Another major acquisition was Illumina Inc (NASDAQ:ILMN), with ARK buying 36,495 shares for about $2.94 million through its ARKK ETF. This purchase adds to ARK’s growing position in the genomic sequencing company, following a pattern of accumulation observed in previous trades.
In the realm of therapeutic innovation, ARK increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by acquiring 53,212 shares, translating to a $2 million investment through ARKK ETF. This move suggests ARK’s continued confidence in the gene-editing company, building upon recent purchases.
Further diversifying its portfolio, ARK bought 34,607 shares of GitLab Inc (NASDAQ:GTLB) at a value of $1.8 million through its ARKW ETF. This investment reflects ARK’s interest in the software development platform, which has been a recurring theme in the fund’s activity over the past week.
The fund also expanded its holdings in Nextdoor Holdings Inc (NYSE:KIND), with a purchase of 177,492 shares valued at approximately $246,713 through the ARKW ETF. This relatively smaller trade nevertheless indicates ARK’s strategy to invest in community-based social networks.
Lastly, ARK trimmed its position in Palantir Technologies Inc (NYSE:NASDAQ:PLTR) by selling 4,791 shares through its ARKF ETF, resulting in proceeds of around $567,541. This sale continues a trend of reducing exposure to the data analytics firm, as seen in previous sessions.
Overall, ARK’s latest trades reflect an ongoing strategy to capitalize on companies poised for disruptive growth, while adjusting holdings to optimize portfolio performance. Investors following ARK’s ETFs will note the fund’s consistent focus on biotech, genomics, and technology sectors, as it navigates the dynamic investment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.